2010
DOI: 10.1007/s00011-010-0185-5
|View full text |Cite
|
Sign up to set email alerts
|

The selective COX-2 inhibitor Etoricoxib reduces acute inflammatory markers in a model of neurogenic laryngitis but loses its efficacy with prolonged treatment

Abstract: Etoricoxib is effective in neurogenic laryngitis for limited periods of administration, indicating that selective COX-2 inhibitors should be evaluated in the future.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2

Citation Types

0
2
0

Year Published

2013
2013
2023
2023

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 8 publications
(2 citation statements)
references
References 37 publications
0
2
0
Order By: Relevance
“…The better protective effect of etoricoxib on anxiolytic behavior in cAD rats than that of naproxen also may be supported by the observation that the total time spent in the outer area (parameter of anxiety) in cAD rats regains the level of control by administration of etoricoxib at the dose of 20 mg/kg body weight on day 14, whereas it did not regain the control value with naproxen at the same dose and time point. The better protection of anxiolytic behavior by etoricoxib in comparison to naproxen may be due to the dual inhibitory action of etoricoxib on the expression and activity of cox-2 [ 33 , 34 ], while naproxen can only inhibit both the cox-1 and cox-2 activity but not their expression [ 35 , 36 ]. Since inducible cox-2 expression and activity were increased during neuroinflammation [ 37 ], the blocking of this enzyme expression and activity by etoricoxib [ 33 , 34 ] in the present study probably inhibited neuroinflammation, and as a result neurodegeneration was also inhibited in these rats.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The better protective effect of etoricoxib on anxiolytic behavior in cAD rats than that of naproxen also may be supported by the observation that the total time spent in the outer area (parameter of anxiety) in cAD rats regains the level of control by administration of etoricoxib at the dose of 20 mg/kg body weight on day 14, whereas it did not regain the control value with naproxen at the same dose and time point. The better protection of anxiolytic behavior by etoricoxib in comparison to naproxen may be due to the dual inhibitory action of etoricoxib on the expression and activity of cox-2 [ 33 , 34 ], while naproxen can only inhibit both the cox-1 and cox-2 activity but not their expression [ 35 , 36 ]. Since inducible cox-2 expression and activity were increased during neuroinflammation [ 37 ], the blocking of this enzyme expression and activity by etoricoxib [ 33 , 34 ] in the present study probably inhibited neuroinflammation, and as a result neurodegeneration was also inhibited in these rats.…”
Section: Discussionmentioning
confidence: 99%
“…The better protection of anxiolytic behavior by etoricoxib in comparison to naproxen may be due to the dual inhibitory action of etoricoxib on the expression and activity of cox-2 [ 33 , 34 ], while naproxen can only inhibit both the cox-1 and cox-2 activity but not their expression [ 35 , 36 ]. Since inducible cox-2 expression and activity were increased during neuroinflammation [ 37 ], the blocking of this enzyme expression and activity by etoricoxib [ 33 , 34 ] in the present study probably inhibited neuroinflammation, and as a result neurodegeneration was also inhibited in these rats. Therefore, the role of cox-2 on the colchicine induced anxiolytic behavior was emphasized from this study.…”
Section: Discussionmentioning
confidence: 99%